		Sheet 1 of 3
ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/719,432	
APPLICANT Spiros Jamas et al.		
FILING DATE	CONFIRMATION NO.	GROUP

5697

1614

	FOREIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
m	AL2	WO 94/04163 A1	03-03-1994	PCT International	
m	AL3	EP 0 416 343 A2	03-13-1991	EPC	

November 21, 2003

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

August 2, 2005

(Use several sheets if necessar

AUG 2 6 2005

EXAMINER DATE CONSIDERED

÷				Oliect B C.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION August 2, 2005 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2732.1016-029	APPLICATION NO. 10/719,432	
		APPLICANT Spiros Jamas et al.		
		FILING DATE November 21, 2003	confirmation no. 5697	GROUP 1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
m	AX	Sherwood, E.R., et al., "Soluble Glucan and Lymphokine-Activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," Chemical Abstracts, 108:179752v (1988).		
m	AW2	Vestnick Federalniho Uradu Pro Vynalezy, 10:111 (1989).		
m	AX2	Vestnick Federalniho Uradu Pro Vynalezy, 11:122-123 (1989).		
'n) AV3 /	Jamas, S. et al., "A Novel Class of Macrophage-Activating Immunomodulators," ACS Symposium Series, Polymeric Drugs and Delivery Systems, Chapter 5, pp. 44-51 (1991).		
egy	AX4	Sasaki, T. et al., "Antitumor Activity of Degraded Products of Lentinan: Its Correlation with Molecular Weight," Gann, 67:191-195 (1976).		
m	AY4	Di Luzio, et al., "Comparative Tumor-Inhibitory and Anti-Bacterial Activity of Soluble and Particulate Glucan," Int. J. Cancer, 24:773-779 (1979).		
E T	AZ4	Burgaleta, C. and Golde, D.W., "Effect of Glucan of Granulopoiesis and Macrophage Genesis in Mice," Cancer Research, 37:1739-1742 (1977).		
M	AR5	Kenyon, A.J., "Delayed Wound Healing in Mice Associated with Viral Alteration of Macrophages," Am. J. Vet. Res., 44(4):652-656 (1983).		
	AT5	Babineau, T., et. al., "Randomized Multicenter Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High Risk Surgery Patients," Surgical Infection Society Meeting, April, 29, 1994.		
	AX5	Norton, J.A., "Biological Therapy of Sepsis", Annals of Surgery, 220(5):599-600 (1994).		
	AY5	"Tumor Necrosis Factor: A Biological Enigma," Science Impact, pp. 5-6, June 1989.		
	AZ5	Dinarello, C.A. and Neta, R., "An Overview on Interleukin-1 as a Therapeutic Agent", <i>Biotherapy</i> , 1:245-254 (1989).		
	AR6	Van der Meer, J.W.M., et al., "Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro," Journal of Leukocyte Biology, 43:216-223 (1988).		
I	AS6	Dinarello, C.A., "Interleukin-1," Reviews of Infectious Diseases, 6(1):51-95 (1984).		

EXAMINER	cm	DATE CONSIDERED
		l

Sheet	3	οf	3

<u> </u>			
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 10/719,432		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Spiros Jamas et al.		<u>-</u>
August 2, 2005	FILING DATE November 21, 2003	confirmation no. 5697	GROUP 1614
(Use several sheets if necessary)	11070111001 21, 2003		1017

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
m	AT6	Duvic, M., et al., "Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome," Arch Dermatol., 123:751-756 (1987)
m	AU6	Adachi, Y., et al., "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)-β-D-Glucans," Chem. Pharm. Bull., 38(4):988-992 (1990).
m	AV6	Sietsma, J.H. and Wessels, J.G.H., "Solubility of (1-3)-β-D/(1-6)-β-D-Glucan in Fungal Walls: Importance of Presumed Linkage between Glucan and Chitin", J. Gen. Microbiology, 125:209-212 (1981).